A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women
Patricia Kissinger, Leandro Mena, Judy Levison, Rebecca A Clark, Megan Gatski, Harold Henderson, Norine Schmidt, Susan L Rosenthal, Leann Myers, David H Martin, Patricia Kissinger, Leandro Mena, Judy Levison, Rebecca A Clark, Megan Gatski, Harold Henderson, Norine Schmidt, Susan L Rosenthal, Leann Myers, David H Martin
Abstract
Objective: To determine if the metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative) for treatment of Trichomonas vaginalis (TV) among HIV+ women.
Methods: Phase IV randomized clinical trial; HIV+ women with culture confirmed TV were randomized to treatment arm: MTZ 2-gm single dose or MTZ 500 mg twice a day 7-day dose. All women were given 2-gm MTZ doses to deliver to their sex partners. Women were recultured for TV at a test-of-cure (TOC) visit occurring 6-12 days after treatment completion. TV-negative women at TOC were again recultured at a 3-month visit. Repeat TV infection rates were compared between arms.
Results: Two hundred seventy HIV+/TV+ women were enrolled (mean age = 40 years, ±9.4; 92.2% African American). Treatment arms were similar with respect to age, race, CD4 count, viral load, antiretroviral therapy status, site, and loss-to-follow up. Women in the 7-day arm had lower repeat TV infection rates at TOC [8.5% (11 of 130) versus 16.8% (21 of 125) (relative risk: 0.50, 95% confidence interval = 0.25, 1.00; P < 0.05)] and at 3 months [11.0% (8 of 73) versus 24.1% (19 of 79) (relative risk: 0.46, 95% confidence interval = 0.21, 0.98; P = 0.03)] compared with the single-dose arm.
Conclusions: The 7-day MTZ dose was more effective than the single dose for the treatment of TV among HIV+ women.
Trial registration: ClinicalTrials.gov NCT01018095.
Keywords: HIV-infected women; Trichomonas vaginalis; metronidazole.
Figures
Source: PubMed